La Jolla Pharmaceutical Stock Forecast, Price & News

-0.10 (-2.70 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume76,493 shs
Average Volume575,437 shs
Market Capitalization$99.17 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

La Jolla Pharmaceutical logo

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.40 out of 5 stars

Medical Sector

47th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

5th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

Is La Jolla Pharmaceutical a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" La Jolla Pharmaceutical stock.
View analyst ratings for La Jolla Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than La Jolla Pharmaceutical?

Wall Street analysts have given La Jolla Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but La Jolla Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,800,000 shares, a decline of 23.1% from the June 15th total of 2,340,000 shares. Based on an average daily volume of 273,600 shares, the days-to-cover ratio is currently 6.6 days. Currently, 6.7% of the shares of the company are short sold.
View La Jolla Pharmaceutical's Short Interest

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for La Jolla Pharmaceutical

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.67 by $0.25. The biopharmaceutical company had revenue of $34.14 million for the quarter, compared to the consensus estimate of $33.40 million.
View La Jolla Pharmaceutical's earnings history

How has La Jolla Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LJPC stock has decreased by 24.9% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LJPC?

1 Wall Street analysts have issued 12 month price objectives for La Jolla Pharmaceutical's shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate La Jolla Pharmaceutical's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 315.5% from the stock's current price.
View analysts' price targets for La Jolla Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the following people:
  • Mr. Larry G. Edwards, Pres, CEO & Director (Age 49, Pay $749.17k)
  • Mr. Michael S. Hearne, CFO & Sec. (Age 58, Pay $186.04k)
  • Dr. Lakhmir S. Chawla, Consultant (Age 50, Pay $478.97k)
  • Ms. Paula Rusu, VP of Operations
  • Ms. Sandra Vedrick, Sr. Director of Investor Relations & HR
  • Mr. Thomas Ouellette, VP of Sales & Marketing
  • Mr. Luke Seikkula, Sr. VP of Pharmaceutical Operations (Age 57)
  • Mr. Stewart M. Kroll, Chief Devel. Officer (Age 62)
  • Mr. Mark D. Williams, Sr. VP of Medical Affairs

What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?

8 employees have rated La Jolla Pharmaceutical CEO George F. Tidmarsh on George F. Tidmarsh has an approval rating of 49% among La Jolla Pharmaceutical's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of La Jolla Pharmaceutical's key competitors?

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $3.61.

How much money does La Jolla Pharmaceutical make?

La Jolla Pharmaceutical has a market capitalization of $99.17 million and generates $33.42 million in revenue each year. The biopharmaceutical company earns $-39,420,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does La Jolla Pharmaceutical have?

La Jolla Pharmaceutical employs 59 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is

Where are La Jolla Pharmaceutical's headquarters?

La Jolla Pharmaceutical is headquartered at 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.